Meribank Biotech , Ltd Profit Margin

Meribank Biotech , Ltd posts a profit margin of -22.56% as of June 2026. That compares with -47.99% in the prior-year period — up 53.0% year over year. That is below the Healthcare sector average of 9.71%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Meribank Biotech , Ltd's profit margin was -47.99%. The latest reading is -22.56% — a 53.0% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 9.71% is typical. Meribank Biotech , Ltd's -22.56% is lower that level. That is roughly 332.4% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Meribank Biotech , Ltd's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -22.56% as of June 2026; use YoY and peer views to separate noise from signal.

Context for 4724.TWO's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 9.71%), and (3) consistency with growth and profitability. This page covers the first two; Meribank Biotech , Ltd's other metric pages and overview cover the third.